Genes help explain GLP‑1 wins
Researchers found genetic differences in almost 28,000 23andMe users that appear to partly explain why GLP‑1 weight‑loss drugs work much better for some people than others — and the same variants link to higher risk of gastrointestinal side effects, so your genes could predict both benefit and pain. (nature.com)
Your body already makes a hormone called glucagon-like peptide 1 after you eat. It acts like a “meal received” signal, slowing stomach emptying and telling the brain you are getting full. (nature.com) Drugs like semaglutide and tirzepatide copy that signal, but they keep it turned on much longer than the natural version. That is why the same class of medicines can lower blood sugar and also produce large weight loss. (nature.com) The puzzle is that the same shot can produce very different results in different people. Some patients lose more than 20% of body weight, while others lose little, and stomach side effects like nausea and vomiting also vary a lot. (nature.com 1) (nature.com 2) Researchers at the 23andMe Research Institute looked for an answer in DNA from almost 28,000 people who said they had used a glucagon-like peptide 1 drug for weight loss. They linked genetic differences to two things at once: how much weight people lost and whether they had gastrointestinal side effects. (nature.com) (23andme.com) One of the strongest signals sat in a gene called GLP1R, which is the instruction manual for the receptor these drugs are designed to hit. If the receptor is the lock, this gene helps shape the lock, so small inherited changes can alter how strongly the drug works. (nature.com) (scientificamerican.com) Another signal showed up in GIPR, a second gut-hormone receptor that tirzepatide targets along with glucagon-like peptide 1. That matters because tirzepatide is a dual-action drug, so variation in that second receptor can change both benefit and side-effect risk in a way semaglutide would not. (nature.com) (statnews.com) The study found that some variants tied to greater weight loss also tracked with higher odds of nausea or vomiting. In plain terms, the same biology that makes the drug hit harder can also make the gut complain louder. (nature.com 1) (nature.com 2) The effect was real but not destiny. Scientific American reported that the variants explain only part of the gap between patients, which means dose, diet, adherence, other medicines, and many genes outside these two receptors still shape the outcome. (scientificamerican.com) (nature.com) 23andMe has already turned the findings into a new glucagon-like peptide 1 report and an interactive tool inside its Total Health service. The near-term use is not “Should you take the drug or not,” but “Which drug, at what dose, and how likely are side effects?” (23andme.com) (eurekalert.org) Doctors are not at the point of ordering a standard DNA test before every prescription. But this paper pushes obesity treatment a step closer to the way cancer drugs are often used now: match the medicine to the biology instead of giving everyone the same starting guess. (nature.com 1) (nature.com 2)
